This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.
The patient or their legal representative is able to sign the written informed consent form and understands and agrees to comply with the study requirements;
Age ≥ 18 years and < 75 years at the time of signing the informed consent form, regardless of gender;
Histologically confirmed esophageal squamous cell carcinoma, confirmed by imaging examinations such as CT, MRI, or PET-CT as locally advanced unresectable ESCC (medically unsuitable for surgery or refusal of surgical intervention), and suitable for cCRT, including: stages II-IVa and certain cases of stage IVb (involving only supraclavicular lymph node metastasis) (AJCC version 8 ) meeting the criteria;
Estimated life expectancy of at least 6 months;
History of other malignancies;
History of fistula caused by primary tumor infiltration;
Patients at high risk of esophageal fistula or with signs of esophageal perforation;
History of esophageal cancer surgery;
Ning Jiang, M.D./Ph.D.
Lead sponsor
Jiangsu Cancer Institute & Hospital
Sponsor institution